Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hip replacement patients may need less blood transfusions with right drug dose

NCT ID NCT03822793

Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different doses of tranexamic acid, a drug that helps blood clot, to see which works best for reducing blood loss during hip replacement surgery. 170 patients were randomly assigned to receive either a placebo or one of three doses of the drug right at the start of surgery. The goal was to find the dose that minimizes hemoglobin drop and the need for blood transfusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid (Exacyl)
What this could lead to
If successful, this study could identify the best dose of tranexamic acid to reduce blood loss and transfusion needs during hip replacement surgery.
What could go wrong
This is a small, single-center phase 2 trial, so results may not apply to all patients. The optimal dose found here needs confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

170 people

The number who actually took part.

Started

Dec 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient requiring primary hip arthroplasty (less than 3 months) * Informed Consent from the patient or their legally authorized representative * Affiliation to French Social Security Healthcare system Exclusion Criteria: * Hip fracture of less than 3 months * Bilateral hip arthroplasty or anterior approach to hip arthroplasty * Haemorrhagic surgery in the previous 2 weeks * Contraindication to tranexamic acid * Contraindication to apixaban * Chronic use of anticoagulant * Pregnancy * Previous participation to this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthropathy of hip are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis, hip

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthropathy of hip

Contacts and locations

Locations

  • CHU Saint-Etienne

    Saint-Etienne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.